RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Board Meeting Intimation For Consider And Approve Audited Financial Statement For Financial Year Ended March 31, 2020
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/08/2020 ,inter alia, to consider and approve Board Meeting Intimation for consider and approve Audited financial statement for financial year ended March 31, 2020 Rubra Medicaments Ltd - 531099 - Announcement under Regulation 30 (LODR)-Change in Registered Office Address
Shifting of registered office of the Company within the local limits to 604, 6th floor, at Meghdoot, Mogul Lines Staff CHSL, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai 400049 Rubra Medicaments Ltd - 531099 - Announcement under Regulation 30 (LODR)-Change in Registered Office Address
Intimation of Board Meeting for shifting of registered office. RUBRA MEDICAMENTS LTD. - 531099 - Shareholding for the Period Ended December 31, 2019
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here RUBRA MEDICAMENTS LTD. - 531099 - Unaudited Financial Result For The Quarter Ended December 31, 2019 Along With Limited Review Report
Unaudited Financial Result For The Quarter Ended December 31, 2019 Along with Limited Review Report Rubra Medicaments Ltd - 531099 - Board Meeting Intimation for Intimation Of Board Meeting
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve Adoption of Quarterly Results for the quarter ended December 31, 2019. Rubra Medicaments Ltd - 531099 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Chief Financial Officer RUBRA MEDICAMENTS LTD. - 531099 - Cash Flow Statement For The Half Year Ended September 30, 2019
Cash Flow Statement For The Half Year Ended September 30, 2019 RUBRA MEDICAMENTS LTD. - 531099 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (LODR), 2015 For The Half Year Ended September 30, 2019
Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (LODR), 2015 For The half Year Ended September 30, 2019